多替拉韦在HIV-1感染婴幼儿、儿童及青少年中的群体药代动力学建模与儿童剂量优化
本研究基于P1093和ODYSSEY临床试验数据,建立多替拉韦群体药代动力学模型,纳入239名0.1至17.5岁、体重3.9至91 kg的儿童。模型预测按年龄/体重带推荐剂量给药后,各体重带谷浓度几何均值与成人50 mg每日一次相当;体重、年龄和剂型为显著协变量;探索性暴露-安全性分析未发现暴露与所选安全性终点或不良事件相关。
要点
- ≥4周龄儿童按年龄/体重带给予多替拉韦,暴露与成人50 mg每日一次相当。
- 体重、年龄和剂型是儿童多替拉韦药代动力学的显著预测因素。
- 探索性分析未发现多替拉韦暴露与所选安全性终点或不良事件相关。
核心结论
- ≥4周龄儿童按年龄/体重带给予多替拉韦可提供与成人历史观察相当的暴露。
- 儿童群体中药代动力学变异性高于成人,但未观察到额外安全性问题。
- 结果支持世界卫生组织当前推荐的儿童体重带多替拉韦给药方案。
研究设计与样本
- 基于P1093和ODYSSEY临床试验数据建立群体药代动力学模型。
- 共纳入N=239名参与者,基线年龄0.1至17.5岁,体重3.9至91 kg,50%为男性,80%为黑人。
- 最终模型为一室模型,一级吸收和消除。
- 模拟各体重带、剂量和剂型的暴露,并与已建立的成人参考数据比较。
- 开展探索性暴露-安全性分析,评估多替拉韦药代动力学参数与所选临床实验室参数及不良事件的关系。
主要发现
- 按推荐剂量给予多替拉韦50 mg每日一次后,所有体重带的预测谷浓度几何均值与成人值相当。
- 体重、年龄和剂型是儿童多替拉韦药代动力学的显著预测因素。
- 探索性暴露-安全性分析未发现多替拉韦暴露与所选安全性终点或不良事件之间存在相关性。
- 儿童群体中观察到的药代动力学变异性高于成人。
关键数值与推荐
- 多替拉韦在≥4周龄儿童中按年龄/体重带给药,可提供与成人历史观察相当的暴露。
- 推荐剂量下各体重带预测谷浓度几何均值与成人50 mg每日一次相当。
临床怎么用
- ≥4周龄HIV-1感染儿童可按年龄/体重带使用多替拉韦,无需因体重、年龄或剂型差异额外调整推荐剂量。
- 临床可参考世界卫生组织当前推荐的儿童体重带剂量方案。
- 儿童中药代动力学变异性较高,临床需关注暴露差异但当前未提示额外安全性信号。
局限性
- 暴露-安全性分析为探索性分析。
- 儿童群体中药代动力学变异性高于成人。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: HIV treatment options remain limited in children. Dolutegravir is a potent and well-tolerated, once-daily HIV-1 integrase inhibitor recommended for HIV-1 infection in both adults and children down to 4 weeks of age. To support pediatric dosing of dolutegravir in children, we used a population pharmacokinetic model with dolutegravir data from the P1093 and ODYSSEY clinical trials. The relationship between dolutegravir exposure and selected safety endpoints was also evaluated. METHODS: A population pharmacokinetic model was developed with data from P1093 and ODYSSEY to characterize the pharmacokinetics and associated variability and to evaluate the impact of pharmacokinetic covariates. The final population pharmacokinetic model simulated exposures across weight bands, doses, and formulations that were compared with established adult reference data. Exploratory exposure-safety analyses evaluated the relationship between dolutegravir pharmacokinetic parameters and selected clinical laboratory parameters and adverse events. RESULTS: A total of N = 239 participants were included, baseline age ranged from 0.1 to 17.5 years, weight ranged from 3.9 to 91 kg, 50% were male, and 80% were black. The final population pharmacokinetic model was a one-compartment model with first-order absorption and elimination, enabling predictions of dolutegravir concentrations in the pediatric population across weight bands and doses/formulations. The predicted geometric mean trough concentration was comparable to the adult value following a 50-mg daily dose of dolutegravir for all weight bands at recommended doses. Body weight, age, and formulation were significant predictors of dolutegravir pharmacokinetics in pediatrics. Additionally, during an exploratory exposure-safety analysis, no correlation was found between dolutegravir exposure and selected safety endpoints or adverse events. CONCLUSIONS: The dolutegravir dosing in children ≥ 4 weeks of age on an age/weight-band basis provides comparable exposures to those historically observed in adults. Observed pharmacokinetic variability was higher in this pediatric population and no additional safety concerns were observed. These results support the weight-banded dosing of dolutegravir in pediatric participants currently recommended by the World Health Organization.
引用
- Chandasana H, Thapar M, Hayes S, et al. Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents. Clin Pharmacokinet. 2023. PMID: 37603217. doi:10.1007/s40262-023-01289-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。